A single-blinded randomized controlled trial evaluating pain and opioid use after dilator placement for second-trimester abortion

• Published in: Contraception (Stoneham) Vol. 103; no. 3; pp. 171 - 177
• Main Authors: Liu, Serena M., Flink-Bochacki, Rachel
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2021
• Subjects: Abortion; Abortion, Induced; Analgesics, Opioid; Dilapan; Dilation and evacuation; Female; Humans; Laminaria; Misoprostol; Osmotic dilator; Pain; Pain - drug therapy; Pregnancy; Pregnancy Trimester, Second; Pain; Laminaria; Osmotic dilator; Abortion; Dilapan; Dilation and evacuation
• ISSN: 0010-7824; 1879-0518
• DOI: 10.1016/j.contraception.2020.11.014

To compare pain levels and medication needs after placement of laminaria vs Dilapan-S, and after dilation and evacuation (D&E). We conducted a single-blinded randomized control trial of patients undergoing D&E at 15 0/7 to 23 6/7 weeks gestation, randomizing to cervical preparation with laminaria or Dilapan-S. We compared pain levels and medication usage following dilator placement (5 minutes; 2, 4, and 8 hours; the following morning) and D&E (1, 4, 24, and 48 hours). Our primary outcome was median change from baseline pain, and secondary outcomes included maximum pain timing and overall narcotic use. We compared baseline characteristics, median pain increases and quantities of narcotics used. We analyzed 67 participants with laminaria (n = 34) and Dilapan-S (n = 33). More Dilapan-S users had a prior vaginal delivery (n = 20, 60.6%) than laminaria users (n = 11, 32.4%), p = 0.02. Maximum median pain was not statistically different (Laminaria: +3.5 (interquartile range [IQR] +0.5, +6.5); Dilapan-S: +3 (IQR +1, +5); p = 0.42. Thirty-seven (63.8%) participants reported higher levels of pain following dilator placement than D&E. Overall, 26 (42.6%) participants used narcotics during their abortion episode, with no difference in median number of tablets between laminaria (2, range 1–8) and Dilapan-S (4.5, range 1–15) participants (p = 0.34). Median pain increase did not differ in participants receiving laminaria or Dilapan-S for cervical preparation prior to D&E. The majority of patients will use a small amount of narcotics if available. The lack of difference in pain between laminaria and Dilapan-S enhances the applicability of pain intervention research across dilator types. With over half of participants using a small amount of narcotics during their D&E episode, pain management should be individualized to patient needs.